Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
May 09 2022 - 08:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that the San
Francisco Business Times and the Silicon Valley Business Journal
ranked Allogene as the highest rated biotechnology company – and
12th company overall – on the 2022 Best Places to Work in the Bay
Area list in the large company category (200-499 employees).
Winning organizations were selected from over 400 competing Bay
Area companies that have created exceptional workplaces that their
employees value highly. Results were based on a survey of employees
measuring engagement and other workplace factors including:
communication and resources, individual needs, manager
effectiveness, personal engagement, team dynamics and trust in
leadership.
“Our people are the heart and soul of Allogene, and this
recognition is a testament to the One Allogene company culture
we’ve worked so hard to build,” said David Chang, M.D., Ph.D.,
President, CEO and Co-Founder of Allogene. “This award is
especially meaningful because it stems from honest, voluntary
employee feedback and truly illustrates our collective mission of
developing life-saving products for patients with cancer.”
On May 1, 2022, Allogene celebrated its four-year anniversary
with its more than 300 employees who together continue to nurture
its One Allogene culture. The Company, which is actively recruiting
new employees, was also recently named a 2022 Best Place to Work by
BioSpace. For more information, visit the Allogene Careers web
site.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to recruit, develop and retain employees; the
ability to develop allogeneic CAR T products for cancer and the
potential benefits of AlloCAR T™. Various factors may cause
differences between Allogene’s expectations and actual results as
discussed in greater detail in Allogene’s filings with the
Securities and Exchange Commission (SEC), including without
limitation in its Form 10-Q for the quarter ended March 31, 2022.
Any forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contacts:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2023 to Mar 2024